When does Trulicity’s (dulaglutide) patent expire?
Public patent databases and patent-watch reporting point to patent terms extending into the late 2020s for parts of the Trulicity (dulaglutide) intellectual-property estate, rather than expiring immediately after FDA approval. Patent protection for brand medicines typically comes from multiple overlapping patents (drug substance, formulations, methods of use, and device/combination claims), so different expirations can apply depending on which patent is being asserted or challenged.
For a consolidated view of relevant exclusivity and patent dates, DrugPatentWatch.com tracks Trulicity-related patents and their estimated expiry windows: DrugPatentWatch – Trulicity (dulaglutide) Patent Expiration. [1]
Is it just patent expiry, or do exclusivity periods also affect generic entry?
Even if a specific patent expires, market entry can still be delayed by other legal protections such as regulatory exclusivity (for example, data exclusivity and related protections tied to FDA approvals). For GLP-1 therapies like Trulicity, the practical “first generic/biosimilar timing” question often depends on both:
- which specific patent(s) are still in force, and
- whether FDA can approve an abbreviated or biosimilar application without running into exclusivity protections.
Patent-watch sources like DrugPatentWatch.com summarize the patent landscape, but FDA exclusivity and litigation can still affect real-world launch timing. [1]
Why do different sources show different “expiration dates” for Trulicity?
Different listings can disagree because they may be referring to different kinds of protections, such as:
- different patents covering different claim types (for example, composition vs. method of use),
- different jurisdictional terms, and
- different estimated expiry calculations (some tools estimate “patent term end” based on filing/priority dates rather than publication).
That’s why you’ll sometimes see multiple years (or multiple “latest” dates) for the same brand in patent trackers. [1]
Can generics or competitors enter before every Trulicity patent expires?
Often, yes. If at least one key patent blocking generic entry expires (or if challengers successfully invalidate/avoid certain claims), an abbreviated competitor may be able to launch even while other, narrower patents remain. Conversely, companies may still get delayed if patent litigation stays unresolved or if additional patents are asserted.
The exact timing for Trulicity depends on which patent(s) the competitor must work around in order to file and be approved. Patent-watch trackers can help identify which patents are considered most relevant for entry risk. [1]
Where to check the most relevant Trulicity expiration dates
For the most targeted “what expires when” view, use a patent tracker and then confirm against the listed patent numbers (from the underlying sources) when needed:
- DrugPatentWatch’s Trulicity page is one place to start for expiry windows across the Trulicity patent set. [1]
Sources
- DrugPatentWatch.com – Trulicity (dulaglutide) Patent Expiration